<DOC>
	<DOCNO>NCT01281696</DOCNO>
	<brief_summary>The main purpose study investigate efficacy bevacizumab , etoposide cisplatin treat breast cancer patient central nervous system metastasis ( include brain parenchymal leptomeningeal metastasis ) .</brief_summary>
	<brief_title>Bevacizumab With Etoposide Cisplatin Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis</brief_title>
	<detailed_description>Brain metastasis increasingly important cause morbidity mortality breast cancer patient . Whole brain radiotherapy ( WBRT ) surgery remain standard treatment brain metastasis . However , median overall survival brain leptomeningeal metastasis 8.5 month 16 week respectively There lack standard treatment brain metastasis progression post WBRT . Chemotherapy consider mostly poor treatment response blood brain barrier . However , question tumor disrupt normal function blood brain barrier . For example , etoposide cisplatin use treatment breast cancer patient brain metastasis . The overall response rate central nervous system ( CNS ) 39 % , disease control rate 60 % , although median overall survival 31 week . The role target therapy actively assess . Recently , phase II study lapatinib patient brain metastases HER2-positive breast cancer show CNS objective response rate 6 % lapatinib monotherapy 20 % lapatinib plus capecitabine . Although result promising , treatment population limit HER2 overexpression breast cancer . Bevacizumab , anti-angiogenic agent , approve combine several chemotherapy agent breast , lung colon cancer . It consider contraindicated patient brain metastasis due possibility intracranial bleeding . However , two study involve use bevacizumab treat brain metastatic tumor non-squamous peripherally locate squamous lung cancer show report brain hemorrhage . In addition , bevacizumab approve treat primary brain aggressive tumor recently . In institution , investigator treat three breast cancer patient multiple brain metastasis use bevacizumab plus etoposide cisplatin ( B-EP ) . All treat least two line chemotherapy brain metastasis occur . All receive WBRT brain metastasis one also receive craniotomy brain tumor resection plus local stereotactic radiosurgery . The follow magnetic resonance imaging ( MRI ) reveal recurrent metastatic brain tumor one patient , recurrence leptomeningeal metastasis another two patient . One patient multiple brain parenchyma metastasis show objective response MRI two cycle B-EP treatment , remain progression free 5 month . The two patient leptomeningeal metastasis intrathecal intraventricular ( via Ommaya reservoir ) methotrexate treatment eight dos . They near stupor B-EP treatment . Both best clinical response full recovery consciousness absence cancer cell cerebrospinal fluid . One survive eight month diagnosis leptomeningeal metastasis , two still alive six month diagnosis leptomeningeal metastasis . Dynamic contrast enhance magnetic resonance imaging ( DCE-MRI ) use various study evaluation anti-angiogenic condition . In breast cancer , DCE-MRI use early predictive marker response . Glioblastoma patient also evaluate DCE-MRI determine reduction vessel permeability bevacizumab treatment . Proton magnetic resonance spectroscopy ( 1H-MRS ) use different benign brain tumor malignant one . The utilization 1H-MRS , especially human brain tumor , couple routine MRI functional MRI technique provide great information concern tumor grade extension characterization normal surround tissue possible imaging technique alone . To analyze proton spectroscopy bevacizumab may give u information mechanism B-EP CNS metastasis . Therefore , investigator propose conduct phase II clinical trial test efficacy B-EP regimen breast cancer patient CNS metastasis along brain DCE-MRI demonstrate antiangiogenesis efficacy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1 . A histological confirmed invasive breast cancer 2 . Patient least one measurable brain metastatic tumor ( ≧10mm T1weighted gadolinium enhance MRI contrastenhanced CT ) leptomeningeal metastasis positive CSF cytology study . 3 . Patient whose brain parenchymal metastatic tumor either progress WBRT , develop new lesion WBRT , CNS metastatic tumor response WBRT accord image study 3 month treatment . Patients leptomeningeal metastasis necessarily need whole brain radiotherapy enrollment . 4 . Patients Her2/neu overexpression amplification allow informed available treatment option lapatinib plus capecitabine . 5 . Patients must adequate organ marrow reserve measure within 14 day prior randomization define : Absolute neutrophil count ≧1,000/mcL Platelets ≧75,000/mcL Total bilirubin ≦ 1.5 X upper normal limit AST ( SGOT ) /ALT ( SGPT ) ≦ 2.5 X upper normal limit ; patient liver metastasis AST ( SGOT ) /ALT ( SGPT ) ≦ 5 X allow Serum creatinine ≦ upper normal limit creatinine clearance ≧50ml/min Hemoglobin≧8.0 gm/dL PTT ≦ upper normal limit ; INR ≦ 1.5 Proteinuria ≤ 1+ , &gt; 1+ , urine protein must ≦ 1 g/24 hour 6 . Patient age 18 75 year 7 . Patient 's life expectancy 2 month 8 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 , 1 , 2 3 9 . All woman childbearing potential must negative pregnancy test obtain within 72 hour start therapy 10 . Patients reproductive potential must use effective contraception ( hormone barrier method birth control ; abstinence ) prior study entry , duration study participation , 2 month completion therapy 11 . Patients ( surrogate ) must able comply study procedure sign inform consent Exclusion criterion : 1 . Prior therapy bevacizumab , sorafenib , sunitinib , VEGF pathwaytargeted therapy 2 . Patients whose CNS metastasis progress developed prior cisplatin treatment 3 . History evidence inherit bleed diathesis coagulopathy risk bleed 4 . History thrombotic disorder 5 . Active gastrointestinal bleeding 6 . Patients history selfreported intracranial hemorrhage 7 . Patients clinical sign symptoms gastrointestinal obstruction require parenteral hydration and/or nutrition obstruction 8 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month first dose bevacizumab 9 . Clinically significant peripheral artery disease 10 . Arterial thromboembolic event within past 6 month , include transient ischemic attack , cerebrovascular accident , unstable angina , myocardial infarction 11 . History gross hemoptysis ( i.e . ≥ 1 teaspoon bright red blood ) 12 . Other malignancy within 5 year except cure basal cell squamous cell skin cancer carcinoma situ cervix 13 . Psychiatric illness social situation would preclude study compliance 14 . Serious nonhealing wound , ulcer , bone fracture 15 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior enrollment 16 . Prior minor surgery needle biopsy within 7 day 17 . Concurrent chronic daily aspirin ( &gt; 325 mg/day ) , dipyridamole , ticlopidine , clopidogrel , cilostazol , nonsteroidal antiinflammatory agent know inhibit platelet function 18 . Concurrent therapeutic anticoagulation , prophylactic anticoagulation venous access device allow 19 . History allergic reaction compound similar chemical composition study drug 20 . Pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>CNS metastasis</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>Leptomeningeal metastasis</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cisplatin</keyword>
</DOC>